Prevalence and association of ARID1A with driver alterations and immune checkpoint inhibitor (ICPi) biomarkers in cell-free circulating tumor DNA (ctDNA) from 27,000 non-small cell lung cancer (NSCLC) patients.

David R. Gandara,Caroline M. Weipert,Jennifer Saam,Jonathan W. Riess,Heinz-Josef Lenz,Razelle Kurzrock

Prevalence and association of ARID1A with driver alterations and immune checkpoint inhibitor (ICPi) biomarkers in cell-free circulating tumor DNA (ctDNA) from 27,000 non-small cell lung cancer (NSCLC) patients.

2020

David R. Gandara
Caroline M. Weipert
Jennifer Saam
Jonathan W. Riess
Heinz-Josef Lenz
Razelle Kurzrock

9523Background: Recent data suggest that the tumor suppressor gene ARID1A is associated with high anti-tumor immunity and may have value as a predictive biomarker for response to ICPi therapy in NS...

Keywords:

Circulating tumor DNA
Cancer research
ARID1A
Medicine
Biomarker (medicine)
immune checkpoint inhibitors
Pathology
non-small cell lung cancer (NSCLC)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations